Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group-Reference-Cited by-同舟云学术

Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group

Published:2015-11-20 Issue:6 Volume:30 Page:1425-1427
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Eichenauer D A,Goergen H,Plütschow A,Wongso D,Behringer K,Kreissl S,Thielen I,Halbsguth T,Bröckelmann P J,Fuchs M,Böll B,von Tresckow B,Borchmann P,Engert A

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2015321.pdf

Reference14 articles.

1. Eichenauer DA, Engert A . VII. Management of nodular lymphocyte-predominant Hodgkin lymphoma. Hematol Oncol 2013; 31: 47–50.

2. Eichenauer DA, Fuchs M, Pluetschow A, Klimm B, Halbsguth T, Boll B et al. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood 2011; 118: 4363–4365.

3. Advani RH, Horning SJ, Hoppe RT, Daadi S, Allen J, Natkunam Y et al. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. J Clin Oncol 2014; 32: 912–918.

4. Schulz H, Rehwald U, Morschhauser F, Elter T, Driessen C, Rudiger T et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 2008; 111: 109–111.

5. Eichenauer DA, Engert A, Andre M, Federico M, Illidge T, Hutchings M et al. Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25: iii70–iii75.

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Where Do We Stand? Where Do We Go?;Cancers;2023-06-23

2. Nodular lymphocyte-predominant Hodgkin lymphoma: current management strategies and evolving approaches to individualize treatment;Expert Review of Hematology;2023-06-20

3. Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma;Hematology;2022-12-09

4. Behandlung des nodulär Lymphozyten-prädominanten Hodgkin Lymphoms;Die Onkologie;2022-04-14

5. Management of children and adults with all stages of nodular lymphocyte predominant Hodgkin lymphoma — All St AGE s : A consensus‐based position paper from the Hodgkin lymphoma subgroup of the UK National Cancer Research Institute;British Journal of Haematology;2022-04